UNSPSC 51145101: Mesocarb

This classification denotes a dopamine agonist with the molecular formula C18H18N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) UMT8MP2NDU, chemically known as sydnone imine, 3-(alpha-methylphenethyl)-n-(phenylcarbamoyl)- but more generally known as mesocarb, which bears US NIH Compound Identifier 71932. European Medicines Agency schedules Mesocarb in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08785MIG.

UNSPSC 51145101 Mesocarb is a Commodity code under which state and local governments procure pharmaceutical products, including naloxone, over-the-counter medications, and generic pharmaceuticals distributed through authorized wholesalers and community health programs. Recent solicitations show jurisdictions buying finished pharmaceutical inventory for public health initiatives and government employee benefit programs, with deliveries coordinated through county health facilities, state pharmacy benefit programs, and multistate cooperative purchasing networks. The work spans product sourcing, regulatory compliance (cGMP, DSCSA, FDA requirements), pricing negotiation across multiple wholesaler channels, and fulfillment logistics. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP) serving state and local members across multiple jurisdictions.

Recent activity clusters in Florida, Texas, and Minnesota. Seminole County issued IFB60459723LAS on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building; bids closed July 26, 2023. The Texas Health and Human Services Commission released RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager arrangements. Minnesota's MMCAP issued a multistate RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), with proposals due March 26, 2026, and contract effectiveness July 1, 2026. The MMCAP solicitation weights price competitiveness at 75 percent and mandates 3 percent administrative fees, $5 million commercial general liability insurance, and compliance with Drug Supply Chain Security Act requirements. No explicit set-aside designations appear across these opportunities.